ArticleJAMA2015
Interventions for Rosacea.
Article in JAMA, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 47 citations in OpenAlex.
- Topical medications for moderate-to-severe rosacea: protocol for a living systematic review and network meta-analysis.BMJ open · 2025Article
- The efficacy and safety of minocycline, metronidazole, ivermectin, and azelaic acid in moderate-to-severe papulopustular rosacea: A systematic review and network meta-analysis.JAAD international · 2025Review
- The treatment of Tofacitinib for rosacea through the inhibition of the JAK/STAT signaling pathway.Archives of dermatological research · 2024Article
- Rosacea in Older Adults and Pharmacologic Treatments.Drugs & aging · 2024Review
- Screening of Diagnostic Biomarkers and Immune Infiltration Characteristics Linking Rheumatoid Arthritis and Rosacea Based on Bioinformatics Analysis.Journal of inflammation research · 2024Article
- Rosacea in children: a review.European journal of pediatrics · 2023Review
- Azelaic Acid Regulates the Renin-Angiotensin System and Improves Colitis Based on Network Pharmacology and Experimentation.ACS omega · 2023Article
- Combined therapy of 5-aminolevulinic acid photodynamic therapy and intense pulsed light for rosacea.Lasers in medical science · 2022Article
- Managing Rosacea in the Clinic: From Pathophysiology to Treatment-A Review of the Literature.The Journal of clinical and aesthetic dermatology · 2020Review
- Recent advances in understanding and managing rosacea.F1000Research · 2018Review
- Topical Ivermectin: Data Supporting Dual Modes of Action in Rosacea.The Journal of clinical and aesthetic dermatology · 2017Review
- Safety of antimalarial medications for use while scuba diving in malaria Endemic Regions.Tropical diseases, travel medicine and vaccines · 2016Review
- Consensus on the therapeutic management of rosacea - Brazilian Society of Dermatology.Anais brasileiros de dermatologiaArticle
Corrections and comments
- Comment on
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
clinical questionWhich interventions are associated with highest efficacy and fewest adverse events for treating rosacea? BOTTOM LINE: There is high-quality evidence that topical brimonidine, azelaic acid, and ivermectin, as well as oral doxycycline and isotretinoin, are associated with improvements in rosacea. Lower-quality evidence is available for topical metronidazole, oral tetracycline, laser and light-based therapy, and topical cyclosporine for ocular rosacea. Most treatments are not associated with higher adverse event rates than placebo.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.